Research Paper

Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation

Piaopiao Wang1,2, Huihui Wang1,2, Qianqian Huang1,2, Can Peng1,2,3,4,5, Liang Yao1,2, Hong Chen1,2, Zhen Qiu1,2, Yifan Wu1,2, Lei Wang1,3,4,5, and Weidong Chen1,2,3,4,5

1. School of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230012, China
2. Institute of Drug Metabolism, Anhui University of Chinese Medicine, Hefei, Anhui, 230012, China
3. Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, Anhui, 230012, China
4. Institute of Pharmacoeconomic, Anhui Academy of Chinese Medicine, Hefei, Anhui, 230012, China
5. Synergetic Innovation Center of Anhui Authentic Chinese Medicine Quality Improvement, Hefei, Anhui, 230012, China

Abstract

Objective: Exosomes (Exos) are membrane-encased vesicles derived by nearly all cell types for intercellular communication and regulation. They also received attention for their use as natural therapeutic platforms and drug delivery system. Classically activated M1 macrophages suppress tumor growth by releasing pro-inflammatory factors. This study investigated the suitability of M1-exosomes (M1-Exos) as drug carrier and their effect on the NF-κB signal pathway and further detected whether macrophages repolarization can potentiate the antitumor activities of chemotherapeutics.

Methods: M1-Exos were isolated from M1-macrophages by ultracentrifugation and characterized by transmission electron, nanoparticle tracking analysis, dynamic light scattering and western blot. Then M1-Exos were used as Paclitaxel (PTX) carriers to prepare a nano-formulation (PTX-M1-Exos). A relatively simple slight sonication method was used to prepare the drug delivery system (PTX-M1-Exos). The cytotoxicity of PTX-M1-Exos on cancer cells was detected by MTT and flow cytometry in vitro. 4T1 tumor bearing mice were used to perform the therapeutic effect of PTX-M1-Exos in vivo.

Results: The expression of caspase-3 in breast cancer cells was increased when co-incubated with macrophages in the presence of M1-Exos in vitro. The production of pro-inflammatory cytokines was increased after exposure of macrophages in M1-Exos. M1-Exos provided a pro-inflammatory environment which enhanced the anti-tumor activity via caspase-3 mediated pathway. The treatment of M1-Exos to the tumor bearing mice exhibit anti-tumor effects in vivo. Meanwhile, the treatment of PTX-M1-Exos demonstrated higher anti-tumor effects than the M1-Exos or PTX group.

Conclusion: The results in our study indicate that the M1-Exos act as the carrier to deliver PTX into the tumor tissues, and also enhance the anti-tumor effects of chemotherapeutics in tumor bearing mice.

Key words: anti-cancer, immunological-chemo therapy, M1-macrophage, M1- exosomes, drug delivery

Introduction

Exosomes (Exos) are 50-150 nm membrane-encased vesicles derived by virtually all cell types and identified in various body fluids [1, 2]. These small vesicles contain various functional molecules including nucleic acids, proteins, and cholesterol [3, 4]. In recent years, much attention had been attracted due to their intercellular roles in communication, signal transduction, diagnosis, regulation of immune response and drug delivery [5-7]. With these features, Exos have promoted many scholars to exploit the natural vesicles as drug carries. Moreover, Exos derived from antigen-presenting cells, which can in
turn activate naïve immune cells. Dendritic cells (DCs) derived Exos promote Natural killer cells (NK) activation [8-10], induce T-cells proliferation and enhance CTL cytotoxicity [11, 12], inhibit tumor cells proliferation, and promote apoptosis [13, 14].

Exos carry RNA and proteins constituents from their parental cells, and have been implicated in signal transduction, tumor immune escape, diagnoses and treatment of some diseases [15, 16]. Macrophages are heterogeneous cells which could be phenotypically polarized in the tumor microenvironment to mount specific functional processes [17] and their phenotypes represent the two extremes of the broad range of macrophage functional states [18]. Macrophages, activated by LPS, can inhibit the growth of tumor by releasing some pro-inflammatory cytokines, inducing stromal destruction, and normalizing the tumor vasculature [19-21]. We posited that Exos derived from pro-inflammatory M1-macrophage cells may be used to potentiate the anti-tumor-activities of chemotherapeutics. Previous studies have proved that Exos derived from M2-macrophages induce the migration, invasion, and metastasis of cancer cells [18, 22] and confer cisplatin resistance in gastric cancer cells [23]. However, Exos secreted from activated macrophages stimulate the release of cytokines (including TNF-α, IL-6, IL-12) which cause activation of naïve recipient immune cells [24]. Additionally, classically activated M1 macrophage secreted Exos propagate pro-inflammatory signals and create a local immune stimulatory microenvironment [25, 26]. The release of pro-inflammatory cytokines, such as TNF-α, induce the apoptosis of cancer cells in tumor tissue which is enhanced by CpG DNA treatment [27]. Therefore, this study focused on whether Exos secreted from pro-inflammatory macrophages could activate the NF-kB pathway of naïve immune cells, promote the release of cytokines to establish a local inflammatory environment, and thus potentiate the ability of chemotherapy drug to kill tumor cells.

In this study, Exos were isolated from M1-macrophage cells media with ultracentrifugation, then we evaluated their potential to activate the NF-kB pathway and to create a pro-inflammatory environment. In addition, we investigated whether the pro-inflammatory environment could potentiate the anti-tumor effects of chemotherapeutics such as paclitaxel. Previous study had stated that Exos secreted from classically activated macrophages enhanced the anti-cancer efficiency of the cancer vaccine through establishing a pro-inflammatory microenvironment in the lymph nodes [36]. The results of our study showed that M1-Exos potentiated the anti-tumor efficacy of chemotherapy by activating NF-kB pathway and creating a pro-inflammatory environment.

Experimental and Materials

Reagents

IFN-γ, thioglycollate Broth (70157), PKH67 (MINI67, green) and DAPI (D9542) were obtained from Sigma (Sigma-Aldrich, USA). Alix (ab186429), Anti-iNOS (ab178945) and Anti-CD63 (ab216130) were obtained from Abcam (Cambridge, MA, UK). Anti-Arg-1 (93668T) and Anti-caspase-3 (#9662) were obtained from Cell Signaling Technology (Danville, USA). PTX was got from Meilun Biotechnology Co., Ltd (Dalian, China). TRITC Phalloidin was got from Solarbio (Beijing, China).

Animals and cell culture

Balb/c mice (4-6 weeks) were purchased from the Laboratory Animal Center of Anhui Medical University (Anhui, China). All animal experiments were approved by the Institutional Animal Care and Use Committee of Anhui University of Chinese Medicine.

Murine breast cancer cells 4T1 and the macrophage cells RAW264.7 were got from Cell Bank for Type Culture Collection of Chinese Academy of Science (Shanghai, China). The 4T1 cultured with RPMI-1640 medium and RAW264.7 cultured with Dulbecco’s modified eagle’s media (DMEM, Hyclone, UT, USA). They all supported with 10% fetal bovine serum, 1% penicillin-streptomycin at 5% CO2 under 37°C.

Preparation of M1 and M2-Exos from cells medium

Fetal bovine serum was centrifuged at 120,000 g (4°C) for 18 h to eliminate Exos [37-39]. To prepare M1 and M2-Exos, about 2.0×106 macrophage cells RAW264.7 were seeded in 100-mm culture dish. Then cells were cultured with IFN-γ (100 ng/mL) or IL-4 (40 ng/mL) for 24 h when they reached about 60%
M2-Exos. Nanoparticle tracking analysis (NTA, z-average diameter and zeta potential of M1 and M2-Exos were measured as triplicates. All samples were measured as triplicates. number-weight diameter and particle concentration. Malvern, UK) was used to estimate the scattering (DLS; Nano-zs30, Malvern, UK) was employed to measure the size, intensity-weighted molecules between the two chambers but not cell translocation. Dynamic light scattering (DLS; Nano-zs30, Malvern, UK) was used to visualize and examine the morphology of M1 and M2-Exos. A drop of M1 or M2-Exos (20 μL) was pipetted into 200 mesh carbon-coated copper grids. The excess fluid was dried with filter paper for 1 min, and the samples were stained with 1% uranium acetate for 1 min. Samples were fluorescent-dried for 10 min and then examined by TEM. Dynamic light scattering (DLS; Nano-zs30, Malvern, UK) was employed to measure the size, intensity-weighted z-average diameter and zeta potential of M1 and M2-Exos. Nanoparticle tracking analysis (NTA, Malvern, UK) was used to estimate the number-weight diameter and particle concentration. All samples were measured as triplicates.

Characterization of M1 and M2-Exos

To determine the presence of M1 and M2-Exos markers, the concentrations of M1 and M2-Exos were analyzed by a Micro BCA Protein Assay kit (Thermo, USA) and western blot was performed to detect TSG101, CD9, and Alix. Transmission electron microscopy (TEM, FEI Tecnai G2 spirit, Czech) was used to visualize and examine the morphology of M1 and M2-Exos. A drop of M1 or M2-Exos (20 μL) was pipetted into 2 mesh carbon-coated copper grids. The excess fluid was dried with filter paper for 1 min, and the samples were stained with 1% ura

Exos internalization in vitro

The membrane intercalating dye PKH67 (Sigma-Aldrich, USA) was used to label Exos [41]. As is shown in manufacturer’s protocol, PKH67 (1.0 μL) was diluted into 150 μL of diluent C (PKH67 solution), 151 μL PKH67 solution was co-cultured with the Exos (150 μL), then the mixed samples were incubated for 10 min at room temperature. The reaction was terminated with 10% Exos-free FBS. Afterwards, the Exos were centrifuged at 120,000 g for 90 min to discard unincorporated dye.

To investigate the Exos internalization in cells, 2×10^5 4T1 cells were seeded into 35 mm glass bottom dish (Corning Costar, Sigma-Aldrich, USA) and cultured for 24 h. PKH67-labeled Exos (green fluorescence, 20 μg/mL) were added to the culture media of 4T1 cells for 2 h, 4 h, and 8 h. Buffered paraformaldehyde (4%) was used to fix the cells before mounted by 0.2% Triton X-100. After cleaning the cells with PBS. The cell nucleus were stained by DAPI (blue fluorescence) and incubated with TRITC phalloidin (TRITC Phalloidin is a dye used to label the cytoskeleton, red fluorescence, Solarbio, China) for 10 min. Fluorescence imaging was observed by confocal laser microscope (FV 1000, Olympus, Japan) and analyzed by flow cytometry using Backman FC500 instrument for the PKH67 fluorescence transfer.

Detection of the NF-κB pathway

To detect the signal pathways associated with the naïve macrophage polarization by M1-Exos, we used the M1-Exos to stimulate the naïve macrophages in vitro. Naïve macrophages were seeded in a 6-well plate containing Exos-free media. M1-Exos (40 μg/mL, 80 μg/mL), M2-Exos (80 μg/mL), IFN-γ (100 ng/mL) or IL-4 (40 ng/mL) was added into the naïve macrophage cells for 12 h in vitro. Thereafter, RNA was extracted by Trizol and cDNA was obtained via RNA transcription kit. The expressions of NF-kB and i-κB were performed by RT-PCR (ABI Step-one Plus, Foster City, CA, USA) via SYBR Green (Bimake, Shanghai, China) assay according to the protocol. The primers were shown in Table S1 (Table S1).

Transwell Assays

To evaluate whether M1-Exos could enhance the activity of caspase-3 by creating an inflammatory environment, breast cancer cells and naïve macrophage cells added M1 (20 μg/mL, 40 μg/mL) or M2-Exos (40 μg/mL) co-cultured in transwell systems with 4 μm pore-size for 12 h (6-well Coring, New York, NY, USA), which allowed free diffusion of molecules between the two chambers but not cell translocation.

RT-PCR Analysis

To determine inflammatory cytokines gene expression in vitro, macrophages were harvested from the transwell assays (upper chamber), and used for RNA extraction with the Trizol assay. Then the expressions of M1 (iNOS) marker and inflammatory cytokines (IL-4, IL-6, IL-10, IL-12 and TNF-α) were performed with RT-PCR.

ELISA assay

To further quantified the release of inflammatory cytokines (IL-4, IL-12 and TNF-α). The media from transwell assays (bottom) were collected and samples were assayed using mouse IL-4, 12 and TNF-α Elisa assay (R&D System, USA) as the manufacturer’s protocol.

Caspase-3 activity assay

Moreover, the breast cancer cells were also collected from the transwell assay (bottom chamber) and the activity of caspase-3 was performed with caspase-3 activity kit (Beyotest, Shanghai, China).
Caspase-3 activity was detected by a SpectraMax M2 microplate reader (Molecular Devices, USA) at 405 nm.

**Preparation of PTX-loaded M1-Exos.**

PTX and M1-Exos were mixed in the ratio of 1:6 (m/m) and sonicated using Model 505 Sonic Dismembrator with 25” tip with the following settings: 20% amplitude, 6 cycles of 30s on/off for 3 min with a 2 min cooling period between each cycle [42, 43]. In order to make the M1-Exos membrane recovery, the mixture was co-cultured at 37°C for 1 h. Then un-encapsulated PTX was removed by centrifugation at 1000 rpm for 10 min [44, 45], and the PTX-M1-Exos pellet was centrifuged at 120,000 g. HPLC was used to measure the amount of loaded PTX in each group. PTX was quantified by a Waters 1290 HPLC systems on a C18 column.

**MTT Assay**

4T1 cells were seeded in 96 multi-well plates (Corning Costar, USA) at a density of 4000 cells per well in the culture medium. The different concentrations (at a PTX dose of 0, 5, 7.5, 15, 25, 30 and 40 μg/mL) of PTX, M1-Exos and PTX-M1-Exos were used to treated 4T1 cells. After 72 h, 20 μL MTT solutions (5 mg/mL) were added to each well and incubated for 4 h at 37°C, and the formazan precipitate was dissolved in DMSO. The multi-well plates were shaken and analyzed by spectro photometry at 570 nm. The IC50 was calculated with GraphPad Prism 7.0.

**Apoptosis assay**

According to the manufacturer, Annexin V-FITC/PI Apoptosis Detection Kit (Mountain View, CA, USA) was used to detect the apoptosis of the tumor cells. Briefly, cells were treated and collected after being washed with PBS. Subsequently, they were re-suspended in 500 μL of binding buffer and incubated in darkness with 5 μL of Annexin V-FITC for 5 min and 5 μL of PI (propidium iodide) for another 5 min at room temperature. Finally they were evaluated by flow cytometry (Beckman Coulter FC 500, Brea, CA, USA).

**Establishment of xenograft tumors**

4T1 cells were harvested and suspended in medium and then 1×10^6 4T1 cells were inoculated into the flanks of each female BALB/c mice (about 20 g). The tumor volume was assessed by measuring the size of the xenografts every three days, and the tumor volume was calculated as V= π× width × length × height /6. To investigate the antitumor effects in vivo, once the tumor volume reached approximately 50 mm³, the mice were divided into four groups randomly (each group n=10). Thereafter, the mice were intravenously injected with PBS, PTX, M1-Exos, and PTX-M1-Exos, (at a PTX dose of 5 mg/kg) and treated every 3 days.

**TUNEL staining and frozen section experiments**

Apoptotic cells in tumor tissues were detected by TUNEL assay according to the standard procedure. After fixed in 4% paraformaldehyde, the tissues were stained by 50 μL TUNEL reaction mixture (Roche) for 60 min at 37°C. The cell nucleus was stained with DAPI and observed through the Olympus microscope (Olympus FV1000, Japan). For frozen sections experiments, PTX-M1-Exos (5 mg/kg of PTX concentration) were labeled with PKH67 reagent and injected to the tumor-bearing mice (i.v.). Two hours later, tissues were obtained for frozen sections experiments to measure the fluorescence intensity.

**H&E staining**

For H&E staining, after the mice were euthanized, tumor tissues were collected and photographed. Tissue samples were fixed in 4% formaldehyde for 24 h, and paraffin-embedded. It was sectioned (5μm sections) and stained with hematoxylin and eosin (H&E). An optical microscope was performed to analyze these slides.

**Western blot**

Tumor tissues were lysed with RIPA buffer which contained proteinase and phosphatase inhibitor cocktail. After centrifugation at 12,000 rpm for 30 min (4°C), the BCA assay was used to measure the protein concentration of the tumor lysates. Protein samples were separated on SDS-polyacrylamide gels and transferred onto PVDF membrane (Millipore, Bedford, MA, USA). Membranes were blocked and incubated with the anti-caspase-3 antibody overnight at 4°C. HRP-conjugated secondary antibody was used to detect the bound primary antibodies. The signals were detected by the chemiluminescence kit (Thermo, USA). The data were quantified by Image J software.

**Statistical analysis**

The data were expressed as mean ± SD. The significance of the difference between two groups was tested by Student’s t-test. All analyses were performed with GraphPad Prism 7.0 (GraphPad Software Inc, San Diego, CA, USA). Differences were considered significant at *P<0.05, **P<0.01, *** P<0.001.
Results

**Isolation, characterization and uptake of Exos derived from Macrophages**

To obtain M1-Exos and M2-Exos, macrophages were treated with IFN-γ (100 ng/mL) or IL-4 (40 ng/mL) for 24h which could induce the polarization of macrophages into M1 or M2 type. The biomarkers of M1 and M2 macrophages were detected by the expression of iNOS and Arg-1(Figure 1A), after which the M1-Exos and M2-Exos were isolated from the conditioned media with ultracentrifugation. The isolation method of Exos was based on differential centrifugation as in previous studies [43, 46]. The surface markers of M1 and M2-Exos were detected as shown in Figure 1B. TEM (Figure 1C-D) was used to reveal the morphology of Exos. The TEM images showed that the Exos were well dispersed, generally spherical nanoparticles. The size was detected by DLS (Figure 1C-D).

To confirm whether Exos could be taken up by cells, the purified Exos were labeled with PKH67 (green fluorescence), which was a fluorescent membrane dye. Thereafter, the labeled-M1-Exos were centrifuged for 2 h to remove free dye. After incubation with PKH67-labeled Exos (2 h, 6 h and 8 h), a punctuated pattern of fluorescence was observed in 4T1 cells, with increasing signal over time. This implied that the M1-Exos internalization was time-dependent [2, 46] (Figure 1E and 1F). Moreover, the results of flow cytometry (Figure S1) further confirmed this conclusion.

**M1-Exos activated the NF-κB pathway of naïve macrophages and promoted the release of cytokines to establish a local inflammatory environment**

To detect the signaling pathway associated with the macrophage polarization by M1-Exos, we used the M1-Exos obtained from the IFN-γ-activated macrophages, to stimulate the macrophage cells in vitro. As shown in Figure 2A, M1-Exos can activate NF-κB pathway with dose-dependent manner. Two concentrations of M1-Exos (20 μg/mL and 40μg/mL) were determined based on exosomal protein concentration. After a 12 h incubation, RNA was extracted. Then RT-PCR was used to detect the expression of NF-κB and i-κB at mRNA level. The results showed that M1-Exos (40 ug/mL) increased the expression of NF-κB and i-κB compared with the control group. Previous study [25] had shown that Exos from LPS-stimulated macrophages induce the activation of NF-κB with dose-dependent way. Similarly, the results of our study revealed the Exos secreted from IFN-γ-stimulated macrophage induced the activation of NF-κB path way. Moreover, it has been reported that Exos, isolated from IFN-γ-stimulated macrophages, which can potentiate the antitumor activity of cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node [36]. To investigate whether the M1-Exos induce the release of inflammatory cytokines and enhance the therapeutic effect of chemotherapeutics, we measured the

![Figure 1. The characterization and uptake of Exos.](http://www.thno.org)
level of apoptosis of 4T1 cancer cells in co-cultured with macrophages, in presence of M1-Exos or M2-Exos. First, macrophages were isolated from the above mentioned co-cultures and RT-PCR was performed to detect the expression profiles of inflammatory cytokines. The analysis showed (Figure 2B) that M1-Exos up-regulated the expression of inflammatory cytokines iNOS, IL-6, and IL-12 and down-regulated the expression levels of IL-4 and IL-10. However, M2-Exos down-regulated the expression levels of IL6, TNF-α, IL-12 and up-regulated the expression of IL4 and IL-10 M2 phenotypes of macrophages. Similarly, the significantly increasing in the production of inflammatory cytokines (IL-4 and TNF-α) were detected by ELISA when macrophages co-cultured with M1-Exos. However, the M2-Exos treated groups showed opposite results (Figure 2C). The cytokines expression indicated that naïve macrophages can be induced into a pro-inflammatory form to produce more Th1 cytokines.

Second, cancer cells apoptosis was detected with caspase-3 activity assay kit (Figure 2D). We found that the activity of caspase-3 was significantly increased in the cancer cells incubated with macrophages together with M1-Exos compared with cancer cells co-cultured with either macrophages or M2-Exos (P<0.05; Figure 2D).

The formulation of PTX-loaded M1-Exos and that anti-tumor effects in vitro

As Exos from M1-polarized macrophages increased the activities of caspase-3 in cancer cells by creating a pro-inflammatory, we selected it as the carrier for deliver PTX to tumor tissues. Also, TEM (Figure 1C and Figure 3 A and B) was used to reveal the morphology of naïve M1-Exos, sonicated M1-Exos and PTX-M1-Exos, and sonication (Figure 3A) did not affect the morphology of M1-Exos [42, 43]. The size was detected by DLS (Figure 3A) and NTA (Figure S 2A-C). The mean size of naïve M1-Exos, sonicated M1-Exos, and PTX-M1-Exos was 75.3 nm, 142.9 nm, and 172.8 nm, respectively. Naïve M1-Exos, sonicated M1-Exos and PTX-M1-Exos were negatively charged in NaCl solution (Figure 3A).

Compared with naïve M1-Exos (75.3 nm), the size of PTX-M1-Exos (172.8 nm) was slightly increased. The change of the size could be attributed partly to the incorporation of PTX into the lipid bilayer of Exos, the surface adsorption due to hydrophobic interaction. Previous studies also found that the size of Exos was increased after drug loading into Exos [47-49]. The morphology and surface markers protein of PTX-M1-Exos were no altered (Figure 3A), which further revealed the suitability of the loading conditions.

The loading capacity of PTX-M1-Exos formulation was analyzed by HPLC (Figure S3). The concentration of PTX in the M1-Exos was obtained from the standard curve generated. The average PTX loading efficiency after sonication was 19.55±2.48%. But the mean loading efficiency after simple mixing was 4.85±1.65%. During sonication, researchers found a formation of transient pores or even reformation of Exos upon sonication allowed diffusion of some substances from the surrounding media into Exos [50]. Moreover, sonication does not affect the

![Figure 2. M1-Exos caused activation of NF-xB signal pathway, induction of cytokines expression in naïve macrophages, and enhanced the activities of caspase-3 in cancer cells. (A) The mRNA expressions level of NF-xB and i-kB were quantified by RT-PCR. (B) M1-macrophages maker and pro-inflammatory cytokines were detected at mRNA level by RT-PCR. (C) The expressions of pro-inflammatory cytokines in the co-cultured system were detected by ELISA. (D) The expression of caspase-3 was determined in vitro. All data were representative of at least three (n=3) independent experiments for each experimental group and was analyzed by Student’s test. (n=3; *P<0.05 **P<0.01, *** P<0.001 vs. the control group).](http://www.thno.org)
membrane-bound proteins significantly (Figure 3A) [42, 43].

We further detected the capacity of PTX-M1-Exos to influence cancer cells survival rate. MDA-MB-231, MCF-7, 4T1, A549, Hep G2 and Hela cells were incubated with media, free-M1 or M2-Exos, free PTX, PTX-M1-Exos and PTX-M2-Exos for 24 h followed by measurement of cell viability by MTT assay. PTX-M1-Exos inhibited cell proliferation with an efficiency way compared with the free PTX group (Figure S4) (Figure S4), however, no significant inhibition effects were observed in the blank-M1-Exos treated group. M2-exosomes promote cancer cells proliferation compared with control, however, the inhibitory effects of PTX-M2-Exos were equal to those of PTX (Figure S5). To further detect the pharmacological impact of PTX encapsulated into M1-Exos, the flow cytometry was used to detect the apoptosis of tumor cells with the treatment of PTX-M1-Exos (Figure 3B, 3C and S6).

Figure 3. The formulation of PTX-loaded M1-Exos and that anti-tumor effects in vitro. (A) The morphological, size, protein marker and zeta potential of sonicated-M1-Exos and PTX-M1-Exos. (B) Cell apoptosis was detected by flow cytometry at 24 h in each group, and (C) Statistical analysis of data. The data shown are mean ± SD (n=3). (D) 4T1 cells were incubated with medium (Control), M1-Exos, free PTX, and PTX-M1-Exos for 24 h at different concentrations of PTX and cell viability was assessed using the MTT assay. PTX-M1-Exos (IC50, 4.30 μg/mL) showed higher cytotoxicity compared to free PTX (IC50, 17.49 μg/mL). (n=6; *P<0.05 **P<0.01, *** P<0.001 vs. the control group).
Next, the anti-proliferative effects of PTX and PTX-M1-Exos on 4T1 cells were determined at different concentrations of PTX (at a PTX dose of 0, 10, 20, 30 and 40 μg/mL) (Figure 3D). Compared with the free PTX (IC_{50} 17.49 μg/mL), the PTX-M1-Exos (IC_{50} 4.30 μg/mL) had better anti-proliferative effects on 4T1 cells (Figure 3D). PTX-M1-Exos also exhibited dose-dependent anti-proliferative effects compared to PTX alone (Figure 3D). Following the treatment with PTX and PTX-M1-Exos, the percentage of apoptotic cells was increased compared with control group. Indeed, previous study [51] had demonstrated that Exos consisted of phospholipid bilayers, which may directly fuse the target cell plasma membrane leading to increase the cellular internalization of the encapsulated drugs. These data revealed that M2-Exos could promote the activities of cancer cell, however, M1-Exos itself does not induce apoptosis in cancer cells, which further confirm the superiority of M1-Exos as a drug carrier.

**M1-Exos enhance efficacy of PTX in vivo**

Encouraged by the above results, we then determined the antitumor effects of PTX-M1-Exos treatment in vivo. 4T1 cells were injected subcutaneously in the flanks of female Balb/c mice to establish the tumor model as in a previous study [52]. The tumor-bearing mice were divided into four groups randomly when the tumor volume about 50 mm$^3$ (each group n=10) and then intravenously injected with therapeutic agents. Then, the anti-tumor activities of PTX-M1-Exos in 4T1 tumor bearing mice were detected. Firstly, tumor volume was measured every 3 days (Figure 4A). In comparison with the PBS groups, tumor volumes were increased gradually (p<0.05) following the treatment with M1-Exos and PTX for 27 days. Interestingly, the significant anti-tumor effects (p<0.001) were observed in the PTX-M1-Exos treated group at 27 days (Figure 4B). Secondly, compared with the PBS and PTX groups, animals in M1-Exos and PTX-M1-Exos groups did not show obvious weight loss during the study period (Figure 4C). The survival rate of mice that treated with PTX-M1-Exos was increased compared with the control (Figure 4D). Taken together, these datasets indicated a strong anti-tumor effect in the PTX-M1-Exos groups.

In order to confirm the effect of PTX-M1-Exos on tumor cells further, the apoptosis related proteins were detected via western blot. Thus, we evaluated the expression level of c-caspase3 in the tumor tissues. Compared with M1-Exos and free PTX treated groups, PTX-M1-Exos treated groups showed a significant inhibitory effect on apoptosis (Figure 4E). The expression of caspase-3 protein increased in M1-Exos, PTX and PTX-M1-Exos treated group (5.2 fold, 3.8 fold, and 2.8 fold, respectively), compared with the control group (Figure 4F).

Meanwhile, the apoptosis of tumor tissues were detected by the TUNEL (terminal deoxynucleotidyl transferase UTP nick end labeling) assay. The results (Figure 4G and 4H) showed that much more positive expression of TUNEL was found in the PTX-M1-Exos treated group, which further confirmed that the PTX-loaded into M1-Exos suppressed tumor growth.

**The M1-Exos co-localization in vivo**

Exos are small vesicles present in many tissues in vivo. To detect the distribution of Exos in vivo, frozen section experiments were carried out on the tissues. The representative fluorescence of the stained tissues was observed with a fluorescence microscope (Figure 5A and 5B). The frozen sections and tumor tissues from liver, spleen and lung showed strong green fluorescence compared with control group. This implied that the DIO-labeled Exos remained in the lung, liver and spleen. Most importantly, the DIO-labeled M1-Exos infiltrated into the tumor tissues which indicated that M1-Exos stimulated the macrophage in tumor tissues.

H&E staining

Chemotherapy is often associated with weight loss, which is a common side effect in treated mice [54]. The potential toxicity of different formulations was assessed in Balb/c mice. Compared with the PBS treated groups, mice in M1-Exos and PTX-M1-Exos groups did not show obvious weight loss (Figure 4C), indicating that there was no overt toxicity caused by the treatments. Zrrvogel found that Exos derived from DCs can eradicate tumors in a murine model [55]. Interestingly, DC-derived Exos have passed Phase I and Phase II in unresectable clinical trials for non-small-cell lung carcinoma [56, 57]. In this study, the pathological changes of various organs were estimated with H&E staining assay. As shown in Figure 6, compared with control, M1-Exos and PTX-M1-Exos did not induce cell degeneration or necrosis in major organs, suggesting a reasonable safety margin in their application.

The nanoparticle PTX-M1-Exos showed high...
anti-tumor effect with low systemic toxicity. This is PTX chemotherapy and the biological therapy provided an excellent complementary treatment. In addition, the therapeutic effect of PTX may influence the mitosis of the nucleus. M1-Exos are endogenous substances hence are more effective delivering PTX into cells. Overall, the multifunctional nano-platform has demonstrated a high potential for application in a chemo-/biological combination therapy.

Figure 4. Detection of anti-tumor effects of M1-Exos, PTX and PTX-M1-Exos in tumor-bearing mice. (A) Representative images of the tumor tissues in each group. (B) Tumor volumes in each group were detected. (n=10 in each group) (C) The survival rates in each group. (D) Body weight changes in each group. (E) Western blot analysis of apoptosis-related protein caspase-3 in tumor tissues. (F) The expression level of caspase-3/β-actin. (G) Representative TUNEL staining for apoptotic cells in the xenograft tumor tissues, the green fluorescence represents apoptotic cells. (H) The quantification of the apoptosis in the tumor tissues. (n=6 in each group). Values are expressed as mean ± SD (n=6; *P<0.05, **P<0.01, ***P<0.001 vs. the control group. Scale bar=100 μm).
Figure 5. The distribution of Exos in vivo. (A) Representative fluorescence images showing bio-distributions of M1-Exos in tumor tissues and organs (heart, spleen, liver, lung, and kidney) 2 h after injection (i.v.) of Dio-labeled Exos (50 μg) into 4T1 tumor-bearing-mice and (B) calculation of accumulative fluorescence signals in major organs and tumor tissue. (n=3 per group; *P<0.05, **P<0.01, ***P<0.001 vs. the control group, Student’s-test). (Scale bar=100 μm).

Discussion

Macrophages are the primary cellular component in the innate immune system which play key functions including regulation of inflammation, phagocytosis, tissue remodeling, metabolism and proliferation [58]. It is well known that nanoparticles are internalized by tumor-associated macrophages (TAMs) in the tumor microenvironment [59-63]. Besides, preclinical study had demonstrated the therapeutic and bioactivity of macrophages [64]. However, the in vivo effects of two forms of macrophages M1-type and M2-type are two-faced. The M1-type macrophage could secrete pro-inflammatory
and exhibit anti-tumor effects, while the M2-type macrophage enhances tumor growth and metastasis. In tumor-bearing mice, the M1-type macrophage exhibited anti-tumor effects via regulating the tumor microenvironment. IFN-γ can induce naïve macrophages into the pro-inflammatory and cytotoxic M1 phenotype which activates anti-tumor immunity [65]. Activated M1-macrophages secrete various inflammatory cytokines (such as IL-1β, TNF-γ, and IL-6), thereby triggering resistance to intracellular parasites and tumor [66, 67]. Especially, previous study indicates that differential modulation of the chemokine system integrates polarized macrophages in pathways responsible for resistance to tumors, immune regulation, tissue repair and remodeling [68]. The Exos possess some characteristics of their parent cells and have attracted much attention with regard to their roles in intercellular communication and signal transduction [5, 6]. Previous studies have revealed that stem cells could be induced into specific lineage by Exos which isolated from differentiated cells [69]. In this study, the Exos were secreted from IFN-γ induced macrophages. Our results shown that the NF-κB pathway was activated by M1-Exos, which was consistent with the results of a previous study that LPS-induced macrophage derived Exos activated the NF-κB pathway [25]. Then, we co-cultured cancer cells with naïve macrophages in the presence of M1-Exos. The mRNA expression of M1-macrophages marker and the pro-inflammatory cytokines was significantly increased [36]. Furthermore, the activity of caspase-3 in cancer cells was significantly increased.

Although PTX represents an important class of antitumor agents and plays an important role in the treatment of various malignant tumors, such as human breast cancer [48], the dose-dependent toxic effect of PTX that has hampered the use of PTX in clinic. Recently, as natural nano-sized drug carriers, Exos have been used to deliver chemotherapy drugs to specific tissues or cell types in vivo [2], especially in the tumor tissues [34]. In this study, M1-Exos were employed to deliver the chemotherapeutic drug PTX to tumor tissues in mice. In this way, they not only acted as carriers but also activated the NF-κB pathway, thereby, potentiating the antitumor effects of drug. Drug loading was accomplished by mixing a PTX solution with the Exos as described previously for other various agents [46, 48]. The size of PTX-M1-Exos (172.8 nm) was modestly increased compared to M1-Exos (75.3 nm). Evidence suggests that may be PTX is partially embedded in the bilayer of phospholipids [48]. The morphology of Exos did not change after PTX loading into the naïve Exos which further confirms the suitability of the loading conditions. A modest decreasing in zeta potential was observed from -17 mV to -12 mV after the loading of PTX which is consistent with the results of a previous study [48].

In vitro, the PTX-M1-Exos co-cultured with MDA-MB-231, MCF-7, 4T1, Hela, G2 and A549 cancer cells showed higher cell cytotoxicity compared with free PTX. Additionally, M1-Exos alone showed no toxicity to these cancer cells which is in line with the findings of another study [53]. In vivo, the 4T1 tumor bearing mice model were established to explore the therapeutic efficacy of PTX-M1-Exos administered through tail intravenous injection. PTX-M1-Exos formulation was tested at a dose of 5 mg/kg based on a previous study [70]. At this dose, the tumor growth was markedly inhibited (p<0.001). The inhibitory effects of M1-Exos alone were almost equal to those of PTX and they were statistically significant (p<0.01). Significant inhibition was produced by M1-Exos alone according to the results of in vivo experiment (Figure 4), and this was attributed to the classically activated M1 macrophages. These results indicate that the M1-Exos not only delivered a higher amount of drug to the tumor sites compared with the free PTX [48], but also inhibited tumor growth by activating macrophages. Our results are consistent with previous study [36], which Exos from IFN-γ-induced macrophages potentiated the effects of a cancer vaccine by creating a pro-inflammatory microenvironment.

For PTX conventional therapy, dose-dependent toxic effects are inevitable. Here, we investigated major organ toxicity induced by PTX-M1-Exos. Treatment with M1-Exos and paclitaxel (5 mg/kg) separately showed no overt toxicity in major organs. Moreover, PTX-M1-Exos, even at a two-fold higher dose (10 mg/kg) compared with the therapeutic dose, did not show any overt organic toxicity.

Systemic administration application of the PTX delivery system suppressed tumor growth significantly, and no obvious toxicity was observed via H&E staining. Our results and other studies [24, 58, 59] show that Exos are superior carriers for specific delivery of therapeutic drugs to tumors. Recently, Choo et al. [53], found that M1-macrophage secrereted Exos-mimetic nano-vesicles will caused repolarization of M2 tumor-associated macrophages (TAM) to M1-macrophages. The polarized M1-macrophages could release pro-inflammatory cytokines which induce antitumor immune response. However, the potential influence of macrophages secrereted endogenous nucleic acids and proteins among other components within Exos on the immune system needs to be further investigated and the possibility of clinical use of Exos requires more experimental support.
Conclusions

This work describes a standard and rapid method of isolating Exos from activated M1-type macrophages by ultracentrifugation and their application in the delivery of drugs to tumor cells. When breast cancer cells co-cultured with macrophages in the presence of M1-Exos, the expression level of caspase-3 and pro-inflammatory Th1-type cytokine were increased. The results showed that the anti-tumor activity of M1-Exos was due to the polarization of macrophages and release of pro-inflammatory cytokines. The anti-tumor effects of PTX was significantly improved when PTX was loaded into M1-Exos. Furthermore, M1-Exos-based chemotherapy enhanced the anti-tumor effects in tumor-bearing mice via regulating apoptosis in vivo. Thus, M1-nacrophages derived Exos may be an effective approach to treat cancer cells in the future.

Abbreviations

Exos: exosomes; M1-Exos: M1-exosomes; M2-Exos: M2-exosomes; PTX: paclitaxel; DCs: Dendritic cells; NK cells: Natural killer cells; CTL: Cytotoxic T lymphocyte; FBS: fetal bovine serum; TEM: transmission electron microscopy; DLS: dynamic light scattering; NTA: nanoparticle tracking analysis; HPLC: high performance liquid chromatography; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide, thiazolyl blue tetrazolium bromide; TUNEL: terminal deoxynucleotidyl transferase UTP nick end labeling; H&E: hematoxylin-eosin staining; TAMs: tumor associates macrophages.

Supplementary Material

Supplementary figures and tables.
http://www.thno.org/v09p1714s1.pdf

Acknowledgements

This work was supported by Natural Science Foundation of Anhui University of Chinese Medicine (2018zzzd04) and National Natural Science Foundation of China (81773988). We show our appreciation to Guoqi Zhu for his help in data analysis.

Author contributions

Piaopiao Wang and Lei Wang designed the study. Piaopiao Wang performed most experimental work and data analyses. Huihui Wang and Zhen Qiu contributed animal model. Liang Yao provided assistance. Weidong Chen edited the manuscript.

http://www.thno.org
Competing Interests

The authors have declared that no competing interest exists.

References

1. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 2015; 77: 13-27.

2. Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 2017; 142: 1-12.

3. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008; 13: 453-461.

4. Cameron LD, Caron LM. Accessory to the crime: functions of cells by transfer of functional Apolipoprotein E. Cell Death Dis. 2018; 9: 434.

5. Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 2017; 142: 1-12.

6. Yu G, Jung H, Kang YY, Mok H. Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulants to lymph nodes. Biomaterials. 2018; 172: 71-83.

7. Hanahan D, Coussens LM. Accessories to the crime: functions of cells by transfer of functional Apolipoprotein E. Cell Death Dis. 2018; 9: 434.

8. Wang J, Wang Z, Mo Y, Zeng Z, Wei P, Li T. Effect of hyperthermic macropinocytosis on the human gastric cancer AGS cells. J Control Release. 2015; 210: 71-76.

9. Guo F, Chang CK, Fan HH, Nie XX, Ren YN, Liu YY, et al. Anti-tumor effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Med Res. 2008; 36: 1342-1353.

10. Eitan E, Zhang S, Witwer KW, Mattson MP. Extracellular vesicle-depleted serum-derived exosomes to deliver immune stimulators to lymph nodes. Biomaterials. 2017; 133: 70-81.

11. Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2016; 150: 287-296.

12. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, et al. RNAi delivery by exosome-mimetic nanoparticles - Implications for targeting e-cancer. Molecules. 2016; 102: 231-251.

13. Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 2017; 142: 1-12.

14. Yu G, Jung H, Kang YY, Mok H. Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulants to lymph nodes. Biomaterials. 2018; 172: 71-83.

15. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine. 2012; 7: 1525-1541.

16. Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2016; 150: 287-296.

17. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine. 2012; 7: 1525-1541.

18. Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens-adjunct co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials. 2016; 111: 55-65.

19. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schifflers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine. 2012; 7: 1525-1541.

20. Ohno S, Takashima M, Sudo K, Ueda S, Ishikawa A, Matsuyma et al. Systemically injected exosomes targeted to EGF receptor antagonist microRNA to breast cancer cells. Mol Ther. 2013; 21: 185-191.

21. Han D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharmac Sin B. 2016; 6: 287-296.

22. Martinez FO, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Mol Cancer. 2014; 13: 265-273.

23. Cheng G, Zhu JY, Zhang ZL, Zhang W, Ren JG, Wu M, et al. Transformation of exosome mimetics into quaternary-dot-labeled nanovehicles for antitumor siRNA delivery. Angew Chem Int Ed Engl. 2015; 54: 1036-1040.

24. Gu JY, Felding-Hansen M. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11: 123-134.

25. Zhang W, Yu ZL, Wu M, Ren JG, Xia HF, Sa GL, et al. Magnetic and Folate Functionalization Enables Rapid Isolation and Enhanced Tumor-Targeting of Cell-Derived Microvesicles. ACS Nano. 2017; 11: 277-290.

26. Huang Z, Xiao B, Huang Z, Ju C, et al. Exosomal transfer of exosomal long RNA species: an emerging cancer antagonist. Mol Cancer. 2018; 17: 75.
55. Zitvogel L, Regnault A, Lozier A, Wolters J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998; 4: 594-600.
56. Morse MA, Garst J, Osada T, Khan S, Hobeka A, Clay TM, et al. A phase I study of desoxosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3: 8.
57. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchar D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016; 5: e1071008.
58. Shapouri-Moghaddam A, Mohammadion S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018; 233: 6425-6440.
59. Zanganeh S, Hutter G, Spitterl R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016; 11: 986-994.
60. Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res. 2011; 17: 5695-5704.
61. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine. 2013; 8: 61-71.
62. Cao Q, Yan X, Chen K, Huang Q, Melancon MP, Lopez G, et al. Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials. 2016; 152: 63-76.
63. Zhu S, Niu M, O’Mary H, Cui Z. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm. 2013; 10: 3525-3230.
64. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015; 27: 462-472.
65. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009; 125: 367-373.
66. Dalton DK, Pitts-Meek S, Keshav S, Figari BS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993; 259: 1739-1742.
67. Mills CD, Kincade K, Alt JH, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000; 164: 6166-6173.
68. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677-686.
69. Narayanan R, Huang CC, Ravindran S. Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells. Stem Cells Int. 2016; 2016: 3808674.
70. Eloy JO, Petrielli R, Topan JF, Antonio HMR, Barcellos JPA, Chesca DL, et al. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces. 2016; 141: 74-82.